NEW YORK (GenomeWeb News) — TheraGenetics has raised $6 million in a Series A round of venture capital financing, the company said Tuesday.  
 
TheraGenetics CEO Richard Kivel said the funds will help expand the company’s IP position and will speed its diagnostic development.
 
The company has developed a series of diagnostics for disorders affecting the central nervous system such as schizophrenia, Alzheimer’s disease, and mood disorders.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.